2 results
Approved WMOPending
Primary objective of the study is the assessment of the dose limiting toxicity (DLT) and the maximal tolerated dose (MTD) of capecitabine and mitomycin-C with concomitant SIBRT in patients with locally advanced anal carcinoma.Secondary objectives…
Approved WMORecruiting
*In the phase Ib study: to assess the feasibility and safety of the addition of nivolumab and/or ipilimumab to MMC/capecitabine chemoradiation of the bladder.*In the phase II study: to assess the impact of the addition of the addition of nivolumab…